INS and metabolic dysfunction-associated steatotic liver disease: The pharmacologic inhibition of ACC was assessed in diet-induced rodent models of NAFLD, showing a significant effect in decreasing hepatic malonyl-CoA levels, hepatic de novo lipogenesis and hepatic insulin resistance with an increase in hepatic ketogenesis [69].